Sugar pill ( DrugBank: - )

8 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
5	進行性核上性麻痺	1
6	パーキンソン病	7
49	全身性エリテマトーデス	1
67	多発性嚢胞腎	1
70	広範脊柱管狭窄症	1
86	肺動脈性肺高血圧症	2
206	脆弱Ｘ症候群	1
210	単心室症	1

5. 進行性核上性麻痺

臨床試験数 : 89 / 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01187888 (ClinicalTrials.gov)	January 2010	20/8/2010	Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Rasagiline in Subjects With Progressive Supranuclear Palsy (Phase III)	Progressive Supranuclear Palsy	Drug: Rasagiline;Drug: Sugar pill	Prof. Dr. Stefan Lorenzl	Teva Pharmaceutical Industries;Ludwig-Maximilians - University of Munich	Terminated	50 Years	80 Years	Both	44	Phase 3	Germany

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02066571 (ClinicalTrials.gov)	March 2015	18/2/2014	Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease	A Phase II, Double-Blind, Placebo-Controlled, Crossover Study to Assess Clinical Benefit and Safety of Droxidopa in the Treatment of Parkinson's Disease	Parkinson's Disease;Freezing of Gait;Cognitive Ability, General	Drug: Droxidopa;Drug: sugar pill	Henry Ford Health System	NULL	Enrolling by invitation	30 Years	N/A	Both	20	Phase 2	United States
2	NCT02259049 (ClinicalTrials.gov)	October 2014	3/10/2014	The Effects of L-Tyrosine on 24 Hour Blood Pressure and Heart Rate in Parkinson's Disease	The Effects of L-Tyrosine on Non-invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Parkinson's Disease	Blood Pressure	Dietary Supplement: L-tyrosine;Dietary Supplement: Sugar Pill	New York Institute of Technology	NULL	Completed	40 Years	84 Years	Both	6	Phase 0	United States
3	NCT01676103 (ClinicalTrials.gov)	September 2012	28/8/2012	The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease	The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease	Parkinson's Disease	Dietary Supplement: Tyrosine;Other: Placebo Comparator:Sugar Pill	New York Institute of Technology	Michael J. Fox Foundation for Parkinson's Research	Completed	50 Years	80 Years	Both	40	Phase 1/Phase 2	United States
4	NCT01351168 (ClinicalTrials.gov)	December 2011	9/5/2011	Use of Zolpidem in Parkinson's Disease	A Randomized, Controlled, Double-Blind, Cross-over Study of Zolpidem for Patients With Parkinson's Disease	Parkinson's Disease	Drug: Levodopa;Drug: Zolpidem first dose;Drug: Zolpidem second dose;Drug: sugar pill	Rush University Medical Center	NULL	Withdrawn	30 Years	75 Years	Both	0	Phase 2	United States
5	NCT01341080 (ClinicalTrials.gov)	December 28, 2010	21/4/2011	Varenicline for Gait and Balance Impairment in Parkinson Disease	Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson Disease	Parkinson Disease	Drug: Varenicline;Drug: Sugar pill	Rush University Medical Center	NULL	Completed	40 Years	90 Years	All	40	Phase 2	United States
6	NCT00794313 (ClinicalTrials.gov)	September 2009	19/11/2008	Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease	Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease	Parkinson's Disease	Drug: Amantadine 300 mg;Drug: Topiramate;Drug: Sugar Pill	Oregon Health and Science University	NULL	Terminated	21 Years	N/A	All	3	N/A	United States
7	NCT00912808 (ClinicalTrials.gov)	October 2005	2/6/2009	Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's Disease	A Study of Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's	Parkinson's Disease	Drug: Donepezil;Drug: Sugar Pill (placebo)	Oregon Health and Science University	NULL	Completed	21 Years	N/A	All	23	N/A	NULL

先頭へ

49. 全身性エリテマトーデス

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01101802 (ClinicalTrials.gov)	March 2006	9/4/2010	Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE)	A Prospective, Randomised, Double-blind, Placebo-controlled Trial Evaluating the Effects of Mycophenolate Mofetil on 'Surrogate Markers' for Atherosclerosis in Female Patients With SLE.	Systemic Lupus Erythematosus;Atherosclerosis	Drug: Mycophenolate mofetil;Drug: sugar pill	Guy's and St Thomas' NHS Foundation Trust	Institute of Child Health, University College London, London, UK.	Completed	18 Years	60 Years	Female	71	Phase 4	United Kingdom

67. 多発性嚢胞腎

臨床試験数 : 221 / 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01853553 (ClinicalTrials.gov)	July 2013	8/5/2013	Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney	ADPKD	Drug: Spironolactone;Drug: Sugar pill	University of Colorado, Denver	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	20 Years	55 Years	All	61	Phase 3	United States

70. 広範脊柱管狭窄症

臨床試験数 : 95 / 薬物数 : 169 - (DrugBank : 61) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 90

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00908375 (ClinicalTrials.gov)	May 2009	21/5/2009	Efficacy of Pregabalin in Patients With Radicular Pain	Efficacy of Pregabalin in Patients With Radicular Pain	Neuropathy; Radicular, Lumbar, Lumbosacral;Failed Back Surgery Syndrome;Spinal Stenosis;Herniated Disc	Drug: Pregabalin;Drug: Sugar Pill	Northwestern University	NULL	Completed	18 Years	64 Years	All	39	Phase 4	United States

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01645826 (ClinicalTrials.gov)	July 2012	18/10/2011	Efficacy Study of Cardizem in Pulmonary Arterial Hypertension	Calcium Channel Blockers in Nitric Oxide Non-responder Pulmonary Arterial Hypertension.	Idiopathic Pulmonary Arterial Hypertension;Primary Pulmonary Hypertension;Pulmonary Arterial Hypertension;Familial Primary Pulmonary Hypertension	Drug: Diltiazem Hydrochloride;Drug: Sugar Pill	University of South Florida	NULL	Withdrawn	18 Years	N/A	All	0	N/A	United States
2	NCT01391104 (ClinicalTrials.gov)	April 2009	7/7/2011	Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension	Reproducibility and Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: Sildenafil;Drug: Sugar Pill	Laval University	NULL	Completed	18 Years	80 Years	Both	22	N/A	Canada

206. 脆弱Ｘ症候群

臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01120626 (ClinicalTrials.gov)	September 2009	7/5/2010	Randomized Controlled Study of Donepezil in Fragile X Syndrome	Augmentation of the Cholinergic System in Fragile X Syndrome: A Double-Blind Placebo-Controlled Randomized Study of Donepezil	Fragile X Syndrome	Drug: donepezil;Drug: sugar pill	Stanford University	National Institute of Mental Health (NIMH);Autism Speaks	Completed	12 Years	29 Years	All	45	Phase 2	United States

210. 単心室症

臨床試験数 : 51 / 薬物数 : 53 - (DrugBank : 22) / 標的遺伝子数 : 32 - 標的パスウェイ数 : 67

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01291069 (ClinicalTrials.gov)	September 2011	4/2/2011	Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients	Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients	Single Ventricle	Drug: Tadalafil Citrate;Drug: Sugar pill	University of Utah	NULL	Completed	8 Years	35 Years	All	20	Phase 1	United States

先頭へ